Purpose: There are new advancements in the modulation of the treatment of patients with early-stage breast cancer, including the use of several molecular profiling tests to identify or select those patients who require additional adjuvant chemotherapy together with hormonal therapy on the basis of a recurrence score. One such tool is EndoPredict (Myriad Genetics; Salt Lake City, UT), which provides support in clinical decision making. The objective of this analysis was to study the landscape of absolute chemotherapy benefit and the likelihood of recurrence within 5 to 15 years in Indian patients with breast cancer who are undergoing EndoPredict testing.
Patients And Methods: This study included 308 patients with hormone-positive, human epidermal growth factor receptor 2-negative early breast cancer. Their postsurgical blocks were analyzed using the EndoPredict test. The MEDCALC statistical tool (Panum Education; Seoul, Republic of Korea) was used to estimate the correlation coefficient and to conduct multiple regression analysis.
Results: On the basis of the EndoPredict EPclin Risk Score, 52.12% of patients were classified as being in the low-risk category and could safely forgo adjuvant chemotherapy. For every unit increase in the EPclin Risk Score, the percentage increase in absolute chemotherapy benefit was 6.82%. Similarly, the correlation between the likelihood of recurrence within 5 to 15 years and the EPclin Risk Score suggested that there is a 10.34% increase in recurrence for each unit of EPclin Risk Score.
Conclusion: The EPclin Risk Score has good prognostic and predictive power; it also provides the range of chemotherapy benefit for Indian patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529538 | PMC |
| http://dx.doi.org/10.1200/GO.20.00250 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Closing the gap: prognostic and predictive biomarker validation for personalized care in a Latin American hormone-dependent breast cancer cohort.
Oncologist
December 2024
Laboratorio de Terapia Molecular y Celular, Fundación Instituto Leloir-CONICET, Ciudad de Buenos Aires, Argentina.
Background: Several guidelines recommend the use of different classifiers to determine the risk of recurrence (ROR) and treatment decisions in patients with HR+HER2- breast cancer. However, data are still lacking for their usefulness in Latin American (LA) patients. Our aim was to evaluate the comparative prognostic and predictive performance of different ROR classifiers in a real-world LA cohort.
View Article and Find Full Text PDFLong-term prospective outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor-positive, HER2-negative early breast cancer.
Breast Cancer Res Treat
August 2024
Department of Obstetrics and Gynecology, Klinikum rechts der Isar, School of Medicine and Health, Technische Universität München, Ismaninger Str. 22, 81675, Munich, Germany.
Purpose: To report the prospective long-term outcome data of patients whose chemotherapy decision was guided by the EndoPredict test.
Methods: Patients with hormone receptor-positive HER2-negative early breast cancer with 0-3 positive lymph nodes were enrolled. The EndoPredict test was carried out on all tumor samples.
Background: The purpose of this study was to evaluate the prognostic value of the multigene EndoPredict test in prospectively collected data of patients screened for the randomized, double-blind, phase III UNIRAD trial, which evaluated the addition of everolimus to adjuvant endocrine therapy in high-risk, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.
Patients And Methods: Patients were classified into low or high risk according to the EPclin score, consisting of a 12-gene molecular score combined with tumor size and nodal status. Association of the EPclin score with disease-free survival (DFS) and distant metastasis-free survival (DMFS) was evaluated using Kaplan-Meier estimates.
Treatment Outcomes according to the EndoPredict Score in ER-Positive, HER2-Negative Early Breast Cancer.
Breast Care (Basel)
December 2022
Department of Surgery, Ewha Womans University College of Medicine, Seoul, Republic of Korea.
Purpose: The purpose of this study was to evaluate the treatment outcomes of estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer according to the risk group using EndoPredict (EP) score.
Patients And Methods: Between 2015 and 2019, 207 patients with ER+/HER2- pN0-N1 early breast cancer who underwent surgery, EP test, and adjuvant radiotherapy were accrued. The EPclin score, which combines the molecular EP score with nodal status and tumor size, was calculated, and patients were divided into EPclin low- or high-risk groups by the cutoff value of 3.
Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer.
Clin Cancer Res
October 2022
Medical School, University of Nottingham, Nottingham, United Kingdom.
Article Synopsis
- The EndoPredict assay, previously validated for post-menopausal women with ER+, HER2- breast cancer, was tested for its effectiveness in predicting outcomes in pre-menopausal women with the same cancer type.
- A study involving 385 pre-menopausal women found that both the EP molecular score and the EPclin score were significant predictors of distant recurrence-free survival (DRFS) over a 9.7-year follow-up, with low-risk patients showing much better survival rates.
- These results suggest that pre-menopausal women classified as low-risk by the EPclin score can safely be treated with endocrine therapy alone, potentially avoiding the need for chemotherapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!